Loading...
XSHG
600645
Market cap1.27bUSD
Oct 09, Last price  
19.10CNY
1D
2.25%
1Q
3.97%
Name

Zhongyuan Union Cell & Gene Eng Corp Ltd

Chart & performance

D1W1MN
XSHG:600645 chart
P/E
76.36
P/S
5.97
EPS
0.25
Div yield, %
—
Shrs. gr., 5y
-0.55%
Rev. gr., 5y
1.98%
Revenues
1.45b
-8.23%
407,355,448392,188,205288,105,421307,749,244255,880,777232,550,901300,342,739361,309,762476,864,593708,994,855837,900,5491,320,846,6901,320,517,6761,386,778,8471,318,893,8551,535,328,6521,554,886,9431,589,723,3331,585,423,1731,454,948,326
Net income
114m
+13.43%
7,784,64511,875,29739,097,7702,124,8718,380,45123,426,18813,898,9037,215,73835,464,994208,353,11537,859,92610,366,52859,252,90949,694,808-126,864,300155,320,085112,986,654106,452,673100,352,117113,831,249
CFO
314m
+9.97%
76,115,125111,679,834121,602,969124,917,732175,925,959110,444,59370,409,955110,722,693221,454,6968,174,936143,667,30870,269,191130,081,956241,490,023244,354,437320,957,061261,890,840299,015,343285,187,932313,633,110
Dividend
Aug 10, 20010.0151 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Vcanbio Cell & Gene Engineering Corp., Ltd, established in 1992 and headquartered in Tianjin, China, primarily focuses on providing cell preparation and cryopreservation services across the People's Republic of China. The company's offerings include the handling and storage of a diverse array of stem cells, such as hematopoietic stem cells derived from umbilical cord blood, umbilical cord mesenchymal stem cells, placental sub-totipotent stem cells, adipose stem cells, and dental stem cells, alongside immune cells. Beyond its core cell banking operations, Vcanbio delivers a spectrum of genetic testing services. These include non-invasive prenatal screening, pharmacogenomic testing for safe medication guidance in both adults and children, and analyses for disease genetics and susceptibility. Additionally, the company supplies essential raw materials for in vitro diagnostics, specifically monoclonal and polyclonal antibodies. Vcanbio is also actively involved in the research, development, manufacturing, and commercialization of various biological products, including genes, proteins, and antibodies, as well as pharmaceutical intermediates, experimental synthetic agents, in vitro diagnostic reagents, and medical devices.

Related entities

Subsidiaries
Tianjin Yuanjufu Business Management Partnership (Limited Partnership)

Key people

Yong Wang
Chairman of the Board, General Manager · since 2009
Haibin Li
Deputy General Manager · since 2016
Hongxiang Shi
Deputy General Manager · since 2016
Chunhua Wang
Deputy General Manager · since 2016
Xuejun Wang
Deputy General Manager · since 2012
Hong Ye
Deputy General Manager · since 2018
Wen'ge Zhang
Executive Deputy General Manager, Director · since 2013
Haifeng Cao
Director · since 2009
Xueliang Sun
Director · since 2011
Independent Director · since 2011
Xiaocheng Liu
Independent Director · since 2011
IPO date
May 04, 1993
Employees
Domiciled in
CN
Incorporated in
CN
Headquarters & legal address
区天津市滨海新区(津南)创意中心A座1002室
滨海新区, TJ 100000
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT